RxDoctor Payments Data

Tanya Carter

Nurse Practitioner · Radnor, PANPI 1407241086

Payments from drug & device makers

$987in general payments, 2019–2025

Across 79 payments — averaging $12.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$238
  • AbbVie$229
  • Braintree Laboratories, Inc.$189
  • Novo Nordisk$120
  • Bristol Myers Squibb$43
  • Gilead$35
  • plus $132 from 7 others

What the payments were for

  • Food & beverage$86788%
  • Gifts$11912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$987 in reported general payments places this provider in the 80th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$49,502
Medicare patients
392
Services billed
691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase15$60,797
MotegrityPrucalopride Succinate43$45,327
LinzessLinaclotide55$39,058
TrulancePlecanatide28$24,695
Mesalamine24$7,238
MovantikNaloxegol Oxalate14$5,777
Famotidine243$3,622
ErythromycinErythromycin Base18$2,770
Omeprazole241$2,713
Pantoprazole Sodium153$2,445
Esomeprazole Magnesium31$2,035
Colestipol Hcl22$1,205
LoperamideLoperamide Hcl38$1,041
Dicyclomine Hcl40$634
Ondansetron Hcl56$580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$229$99,85570 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$14$45,32743 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$238$24,69528 claims
Redhill Biopharma Inc.Movantik$22$5,77714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Radnor

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →